Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

Benzer Materyaller

• Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
  Yazar:: Gerd R Burmester, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-10-01)
• Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
  Yazar:: Gabay, Cem, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis
  Yazar:: Boyapati, Anita, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
  Yazar:: Genovese, Mark C, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
  Yazar:: Strand, Vibeke, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)